Source: Zacks

Sanofi: Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications

SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.

Read full article »
Annual Revenue
$50-100B
Employees
50-100K
Paul Hudson's photo - CEO of Sanofi

CEO

Paul Hudson

CEO Approval Rating

63/100

Read more